Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Lisata Therapeutics, Inc. Stockholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2020			1,292,000
Beginning Balance at Dec. 31, 2020	$ 32,242	$ 32,496	$ 1	$ 458,766	$ (13)	$ (425,550)	$ (708)	$ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,466)	(27,466)				(27,466)
Unrealized loss on marketable securities	(57)	(57)			(57)
Share-based compensation (in shares)			35,000
Share-based compensation	1,757	1,757		1,757
Net proceeds from issuance of common stock (in shares)			2,659,000
Net proceeds from issuance of common stock	85,500	85,500	$ 3	85,497
Proceeds from option exercises	24	24		24
Ending Balance (in shares) at Dec. 31, 2021			3,986,000
Ending Balance at Dec. 31, 2021	92,000	92,254	$ 4	546,044	(70)	(453,016)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(54,225)	(54,225)				(54,225)		0
Unrealized loss on marketable securities	52	52			52
Share-based compensation (in shares)			97,000
Share-based compensation	2,367	2,367		2,367
Net proceeds from issuance of common stock (in shares)			11,000
Net proceeds from issuance of common stock	$ 43	43		43
Proceeds from option exercises (in shares)	1,227,776		3,773,000
Proceeds from option exercises	$ 26,098	26,098	$ 4	26,094
Foreign currency translation adjustment	(11)				(11)
Ending Balance (in shares) at Dec. 31, 2022			7,867,000
Ending Balance at Dec. 31, 2022	$ 66,324	$ 66,578	$ 8	$ 574,548	$ (29)	$ (507,241)	$ (708)	$ (254)